Literature DB >> 15369697

Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.

Feng Yan1, Bryan L Roth.   

Abstract

kappa-opioid receptors (KORs) represent the principal site of action of dynorphin and related neuropeptides. Recently, Salvinorin A--a naturally occurring neoclerodane diterpene hallucinogen was identified to be a highly selective KOR agonist. In this brief review we summarize the known chemistry, pharmacology and biology of salvinorin A. Because salvinorin A profoundly alters human consciousness and perception, a study of how salvinorin A exerts its actions on KORs may yield novel insights into the molecular and cellular basis of uniquely human higher cortical functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15369697     DOI: 10.1016/j.lfs.2004.07.008

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  24 in total

1.  Salvinorin A pretreatment preserves cerebrovascular autoregulation after brain hypoxic/ischemic injury via extracellular signal-regulated kinase/mitogen-activated protein kinase in piglets.

Authors:  Diansan Su; John Riley; William M Armstead; Renyu Liu
Journal:  Anesth Analg       Date:  2011-11-10       Impact factor: 5.108

2.  A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.

Authors:  Nidhi Singh; Gwénaël Chevé; David M Ferguson; Christopher R McCurdy
Journal:  J Comput Aided Mol Des       Date:  2006-09-29       Impact factor: 3.686

3.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

Review 4.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

5.  Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.

Authors:  Zhong Zheng; Xi-Ping Huang; Thomas J Mangano; Rodger Zou; Xin Chen; Saheem A Zaidi; Bryan L Roth; Raymond C Stevens; Vsevolod Katritch
Journal:  J Med Chem       Date:  2017-04-03       Impact factor: 7.446

6.  O6C-20-nor-salvinorin A is a stable and potent KOR agonist.

Authors:  Shun Hirasawa; Min Cho; Tarsis F Brust; Jeremy J Roach; Laura M Bohn; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-01-31       Impact factor: 2.823

7.  Evolution and origins of the Mazatec hallucinogenic sage, Salvia divinorum (Lamiaceae): a molecular phylogenetic approach.

Authors:  Aaron A Jenks; Jay B Walker; Seung-Chul Kim
Journal:  J Plant Res       Date:  2010-12-02       Impact factor: 2.629

8.  A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats.

Authors:  Aashish S Morani; Susan Schenk; Thomas E Prisinzano; Bronwyn Maree Kivell
Journal:  Behav Pharmacol       Date:  2012-04       Impact factor: 2.293

Review 9.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

10.  Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways.

Authors:  Gregory P McLennan; Alexi Kiss; Mayumi Miyatake; Mariana M Belcheva; Kari T Chambers; John J Pozek; Yasmin Mohabbat; Robert A Moyer; Laura M Bohn; Carmine J Coscia
Journal:  J Neurochem       Date:  2008-11-10       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.